MySmarTrend
← Insider Monitor
Editas Medicine, Inc. logo
EDIT

Editas Medicine, Inc.

Nasdaq · Biological Products, (No Diagnostic Substances)

1
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Editas Medicine develops gene editing therapies based on CRISPR technology, aiming to treat genetic diseases by directly repairing or altering disease-causing genes in patients.

Industry
Biological Products, (No Diagnostic Substances)
Headquarters
Cambridge, MA
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICERSell$2KSep 3, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for EDIT.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable EDIT activity by email

Free alerts for the insider and congressional trades worth watching.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.